The congenital immunodeficiency disorders in which the defect has been clearly traced to the stem cell can be cured with allogeneic stem-cell transplantation (SCT) from an unaffected donor. Widespread application of this treatment modality has been tempered by the fact that risk-benefit considerations do not always favor a procedure that carries a significant risk for morbidity and mortality. Some malignant disorders of childhood eventually have to be treated by an autologous or allogeneic SCT, however nonmalignant disorders can also be treated with this approach. This article reviews the current status of SCT for nonmalignant inherited immunodeficiency disorders.

Download full-text PDF

Source

Publication Analysis

Top Keywords

stem cell
8
immunodeficiency disorders
8
sct nonmalignant
8
[hematopoietic stem
4
cell transplant
4
transplant combined
4
combined immunodeficiency
4
immunodeficiency syndromes
4
syndromes childhood
4
childhood optimal
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!